Government jobs • Exam updates • PreparationIndependent information portal
RojgarRankYOUR NEXT STEP STARTS HERE
Current Affairs

India Launches Awiqli, World’s First Once-Weekly Basal Insulin

By Published

On 9 July 2026, India introduced Awiqli, the world's first once-weekly basal insulin developed by Novo Nordisk. This insulin contains insulin icodec and is approved in India for adults with both Type 1 and Type 2 diabetes. Awiqli reduces injection frequency from daily (365 injections/year) to weekly (52 injections/year), administered via a FlexTouch pen. The insulin icodec molecule binds to albumin, extending its action to seven days. The 700-unit pack is priced at Rs 2,611, about 30-40% less expensive per unit than existing daily basal insulin. India is the seventh country worldwide to launch this product. Clinical trials indicate glycaemic control comparable or better than daily basal insulin, with some increased hypoglycaemia risk among certain Type 1 patients. This launch addresses India's large diabetes burden and helps reduce insulin therapy initiation delays linked to injection fears.

On this page

Key Facts

  • Launch Date: 9 July 2026
  • Product Name: Awiqli
  • Active Ingredient: Insulin icodec
  • Manufacturer: Novo Nordisk (Danish pharmaceutical company)
  • Indications in India: Adults with Type 1 and Type 2 diabetes
  • Dosage: Once-weekly basal insulin injection
  • Delivery Method: FlexTouch pen device
  • Price: Rs 2,611 for a 700-unit pack
  • Cost Advantage: Approximately 30-40% lower per unit than daily basal insulin
  • India's Position: Seventh country globally to introduce Awiqli

Background & Context

Basal insulin, also known as background insulin, helps maintain blood glucose levels between meals and during sleep in diabetes patients. Daily basal insulin regimens require 365 injections yearly, leading to patient apprehension and delays in therapy initiation—commonly averaging 7 to 9 years in India. Awiqli introduces an innovative once-weekly insulin therapy, reducing injection frequency to 52 times annually.

Insulin icodec, the active molecule in Awiqli, binds reversibly to albumin, the most abundant protein in human plasma, prolonging its duration of action to 7 days. This pharmacokinetic property supports once-weekly dosing.

Clinical trials demonstrate that Awiqli achieves glycaemic control comparable or superior to daily basal insulin. However, there is an observed increased incidence of hypoglycaemia (abnormally low blood glucose) among some Type 1 diabetes patients using Awiqli.

Why This Matters for Exams / Exam Relevance

Knowledge about India's launch of Awiqli is important for competitive exams focused on health, medicine, and pharmaceutical developments. Candidates should be familiar with key details such as product name, active ingredient, launch date, manufacturer, target indications (Type 1 and 2 diabetes), cost advantages, and India's position as the seventh country to adopt the drug.

Understanding the challenges of diabetes management in India—including delayed insulin initiation due to injection fear—and how Awiqli addresses this through reduced injection frequency can be vital for medical, pharmacology, and health policy contexts in exams.

Points to Remember

  • Awiqli is the world's first once-weekly basal insulin.
  • It contains insulin icodec, binding to albumin to extend action for 7 days.
  • Approved in India for both Type 1 and Type 2 diabetes in adults.
  • Delivered via a FlexTouch pen device.
  • Priced at Rs 2,611 per 700-unit pack, approximately 30-40% cheaper per unit compared to daily insulin.
  • India is the seventh country globally to launch Awiqli; in the US, approval is only for Type 2 diabetes.
  • Hypoglycaemia risk may be higher in some Type 1 patients receiving Awiqli compared to daily basal insulin.
  • Addresses significant diabetes treatment challenges in India, notably injection-related apprehension and delayed insulin initiation (on average 7 to 9 years).
← Back to Current Affairs